Scientists discover a surprising link between vitamin C and cancer survival
Daily doses of vitamin C show a surprising survival advantage in patients with precancerous blood disorders and early-stage blood cancers. A phase two randomized clinical trial revealed that participants taking the supplement experienced fewer adverse events and reduced death rates by nearly half. Peter A. Jones noted that vitamin C acts as a powerful epigenetic drug. While the trial missed its primary cellular-growth endpoint, the exploratory survival signals prompted researchers to plan a larger study.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ A clinical trial suggests taking vitamin C daily could improve survival in people with precancerous blood disorders and early-stage blood cancers.
- ✓ Patients receiving the vitamin C supplement had fewer adverse events and showed a survival advantage.
- ✓ Vitamin C can increase the activity of cellular proteins known as TET enzymes.
- ✓ Peter A. Jones described vitamin C as a powerful epigenetic drug.
What changed
A phase two randomized clinical trial demonstrated that daily vitamin C supplementation yields favorable exploratory survival signals in patients with pre-cancer blood disorders.
Live updates
-
Vitamin C Shows Survival Benefits in Blood Disorder Trials
Daily doses of vitamin C show a surprising survival advantage in patients with precancerous blood disorders and early-stage blood cancers. A phase two randomized clinical trial revealed that participants taking the supplement experienced fewer adverse events and reduced death rates by nearly half. Peter A. Jones noted that vitamin C acts as a powerful epigenetic drug. While the trial missed its primary cellular-growth endpoint, the exploratory survival signals prompted researchers to plan a larger study.
Why it matters
The investigation examined oral vitamin C in patients with conditions such as clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes. Researchers observed that the everyday vitamin can boost the activity of TET enzymes, which regulate gene expression. This finding introduces a potential low-cost intervention strategy for halting the progression of pre-leukemic diseases.
What is confirmed
- A clinical trial suggests taking vitamin C daily could improve survival in people with precancerous blood disorders and early-stage blood cancers.
- Patients receiving the vitamin C supplement had fewer adverse events and showed a survival advantage.
- Vitamin C can increase the activity of cellular proteins known as TET enzymes.
- Peter A. Jones described vitamin C as a powerful epigenetic drug.
- The primary cellular-growth endpoint did not differ from placebo in the phase 2 randomized trial.
Still unconfirmed
- Daily vitamin C cut deaths nearly in half in the randomized blood cancer trial.
What to watch next
- Initiation and results of a larger study following the long-term follow-up pattern.
- Further investigation into overall survival benefits for patients with CCUS and lower-risk MDS.
confidence 90%Sources used for this update (13)
- www.sciencedaily.com — Vitamin C News -- ScienceDaily
- Science Daily — Scientists discover a surprising link between vitamin C and cancer survival
- CancerNetwork — Is Vitamin C an Epigenetic Interception Strategy in Pre-Leukemic Disease?
- open.kg — Scientists have discovered an astonishing link between vitamin C and survival in cancer.
- www.dailykos.com — GNR for Friday, October 23: We don’t need permission - Daily Kos
- www.sciencedaily.com — Scientists discover a surprising link between vitamin C and ...
- www.newsweek.com — Common Vitamin Shows Surprising Result in Pre-Leukemia Trial
- welltica.com — Daily vitamin C cut deaths nearly in half in a randomized ...
- www.cancernetwork.com — Is Vitamin C an Epigenetic Interception Strategy in Pre ...
- www.womenfitness.net — Vitamin C Linked To Fewer Deaths in Blood Disorder Trial
- Bioengineer.org — Vitamin C trial yields exploratory survival signal in pre ...
- www.sciencedaily.com — Leukemia News -- ScienceDaily
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community